Literature DB >> 23750875

Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study.

M J Manco-Johnson1, J Sanders, N Ewing, N Rodriguez, M Tarantino, T Humphries.   

Abstract

Although many people with haemophilia discontinue prophylaxis in their late teens or early adulthood, the consequences of this decision are largely not known. This 18-month, observational, case-controlled, multicentre study evaluated long-term prophylaxis and the consequences of switching from prophylaxis to on-demand treatment in late teens and young adults with severe haemophilia A. Participants with haemophilia (aged 14-29 years) on prophylaxis ≥ 60% of the time for the 5 years before study entry were enrolled into 1 of 2 prospective or 1 retrospective group. Group 1 was prophylaxis, group 2 had voluntarily discontinued prophylaxis ≤ 12 months before study entry and group 3 had voluntarily discontinued prophylaxis ≥ 13 months before study entry. Assessments included bleeding frequency (primary endpoint), Haemo-QoL-A health-related quality of life (HRQoL) scores, Gilbert score, development of target joints, Haemophilia Activities List, Godin Leisure-Time, treatment satisfaction and State-Trait Anxiety Inventory (secondary and exploratory endpoints). Descriptive statistics were provided for all variables. Thirty-eight participants (group 1, n = 22; group 2, n = 5; group 3, n = 11; median age, 19.5 years) were enrolled. The median annualized number of bleeding events was 0, 4.8 and 24 in groups 1, 2 and 3 respectively. HRQoL was lower in participants who discontinued prophylaxis vs. those who remained on prophylaxis. Changes in the remaining secondary and exploratory variables were small, but were generally worse in participants who discontinued prophylaxis. Following a switch from prophylaxis to on-demand therapy, the number of bleeding events increased and HRQoL worsened in late teens and young adults with severe haemophilia A.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  adolescents; factor VIII therapy; haemophilia; on-demand therapy; prophylaxis; quality of life; switching

Mesh:

Substances:

Year:  2013        PMID: 23750875     DOI: 10.1111/hae.12177

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

2.  Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada.

Authors:  J St-Louis; D J Urajnik; F Ménard; S Cloutier; R J Klaassen; B Ritchie; G E Rivard; M Warner; V Blanchette; N L Young
Journal:  BMC Hematol       Date:  2016-05-05

3.  Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.

Authors:  Terry Mizrahi; Jean St-Louis; Nancy L Young; Francine Ménard; Nichan Zourikian; Evemie Dubé; Georges E Rivard
Journal:  BMC Hematol       Date:  2016-11-08

Review 4.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123

Review 5.  Measuring therapeutic relationship in the care of patients with haemophilia: A scoping review.

Authors:  Erin McCabe; Maxi Miciak; Liz Dennett; Patricia Manns; Christine Guptill; Jeremy Hall; Douglas P Gross
Journal:  Health Expect       Date:  2018-08-29       Impact factor: 3.377

6.  Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study.

Authors:  Gili Kenet; Yeu-Chin Chen; Gillian Lowe; Charles Percy; Huyen Tran; Annette von Drygalski; Marc Trossaërt; Mark Reding; Johannes Oldenburg; Maria Eva Mingot-Castellano; Young-Shil Park; Flora Peyvandi; Margareth C Ozelo; Johnny Mahlangu; Jennifer Quinn; Mei Huang; Divya B Reddy; Benjamin Kim
Journal:  J Clin Med       Date:  2021-12-18       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.